PMID- 27146751
OWN - NLM
STAT- MEDLINE
DCOM- 20170421
LR  - 20181202
IS  - 1998-4774 (Electronic)
IS  - 0019-509X (Linking)
VI  - 53
IP  - 1
DP  - 2016 Jan-Mar
TI  - Practical recommendation for rash and diarrhea management in Indian patients 
      treated with tyrosine kinase inhibitors for the treatment of non-small cell lung 
      cancer.
PG  - 87-91
LID - 10.4103/0019-509X.180863 [doi]
AB  - Tyrosine kinase inhibitors (TKIs) are a pharmaceutical class of small molecules, 
      orally available with manageable safety profile, approved worldwide for the 
      treatment of several neoplasms, including lung, breast, kidney and pancreatic 
      cancer as well as gastro-intestinal stromal tumours and chronic myeloid 
      leukaemia. In recent years, management of lung cancer has been moving towards 
      molecular-guided treatment, and the best example of this new approach is the use 
      of the tyrosine kinase inhibitors (TKIs) in patients with mutations in the 
      epidermal growth factor receptor (EGFR). The identification of molecular 
      predictors of response can allow the selection of patients who will be the most 
      likely to respond to these tyrosine kinase inhibitors (TKIs). Gastrointestinal 
      (GI) adverse events (AEs) are frequently observed in patients receiving EGFR 
      tyrosine kinase inhibitor therapy and are most impactful on the patient's quality 
      of life. Dermatologic side effects are also relatively common among patients 
      treated with EGFR inhibitors. Evidence has emerged in recent years to suggest 
      that the incidence and severity of rash, positively correlated with response to 
      treatment.These skin disorders are generally mild or moderate in severity and can 
      be managed by appropriate interventions or by reducing or interrupting the dose. 
      Appropriate and timely management make it possible to continue a patient's 
      quality of life and maintain compliance; however if these adverse events (AEs) 
      are not managed appropriately, and become more severe, treatment cessation may be 
      warranted compromising clinical outcome. Strategies to improve the assessment and 
      management of TKI related skin AEs are therefore essential to ensure compliance 
      with TKI therapy, thereby enabling patients to achieve optimal benefits. This 
      article provides a consensus on practical recommendation for the prevention and 
      management of diarrhoea and rash in Non-Small Cell Lung Cancer (NSCLC) patients 
      receiving TKIs.
FAU - Parikh, P
AU  - Parikh P
FAU - Prabhash, K
AU  - Prabhash K
AD  - Department of Medical Oncology, Lung/Head and Neck Cancer, Tata Memorial 
      Hospital, Mumbai, Maharashtra, India.
FAU - Naik, R
AU  - Naik R
FAU - Vaid, A K
AU  - Vaid AK
FAU - Goswami, C
AU  - Goswami C
FAU - Rajappa, S
AU  - Rajappa S
FAU - Noronha, V
AU  - Noronha V
FAU - Joshi, A
AU  - Joshi A
FAU - Chacko, R T
AU  - Chacko RT
FAU - Aggarwal, S
AU  - Aggarwal S
FAU - Doval, D C
AU  - Doval DC
LA  - eng
PT  - Journal Article
PT  - Review
PL  - India
TA  - Indian J Cancer
JT  - Indian journal of cancer
JID - 0112040
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Protein Kinase Inhibitors)
RN  - EC 2.7.10.1 (EGFR protein, human)
RN  - EC 2.7.10.1 (ErbB Receptors)
SB  - IM
MH  - Antineoplastic Agents/adverse effects/therapeutic use
MH  - Carcinoma, Non-Small-Cell Lung/*drug therapy/pathology
MH  - Diarrhea/chemically induced/*prevention & control
MH  - ErbB Receptors/antagonists & inhibitors
MH  - Exanthema/chemically induced/*prevention & control
MH  - Humans
MH  - Lung Neoplasms/*drug therapy/pathology
MH  - Practice Guidelines as Topic
MH  - Protein Kinase Inhibitors/*adverse effects/therapeutic use
EDAT- 2016/05/06 06:00
MHDA- 2017/04/22 06:00
CRDT- 2016/05/06 06:00
PHST- 2016/05/06 06:00 [entrez]
PHST- 2016/05/06 06:00 [pubmed]
PHST- 2017/04/22 06:00 [medline]
AID - IndianJournalofCancer_2016_53_1_87_180863 [pii]
AID - 10.4103/0019-509X.180863 [doi]
PST - ppublish
SO  - Indian J Cancer. 2016 Jan-Mar;53(1):87-91. doi: 10.4103/0019-509X.180863.